Search
Publications 2003-2013

1 Associations between immune depression and cardiovascular events in HIV infection. CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, AD Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, M Law, J Lundgren.
AIDS. 13 November 2013; Volume 27; Issue 17; 2735-2748. abstract

2 Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, A d'Arminio Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin.
BMC Infect Dis. 2013 Oct 9;13(1):471. PMID:24106926. abstract

3 Association Between Antiretroviral Exposure and Renal Impairment Among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. L Ryom, A Mocroft, O Kirk, SW Worm, DA Kamara, P Reiss, M Ross, CA Fux, P Morlat, O Moranne, C Smith, JD Lundgren; on behalf of the D:A:D study group.
J Infect Dis. 2013 May;207(9):1359-1369. abstract

4 Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. H Kovari, CA Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber.
Clin Infect Dis. 2013 Mar;56(6):870-9. abstract

5 Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D Study. CA Sabin, L Ryom, H Kovari, O Kirk, S de Wit, M Law, P Reiss, F Dabis, C Pradier, W El Sadr, AD Monforte, D Kamara, AN Phillips, JD Lundgren JD.
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63. abstract

6 Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease eventsAD Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin.
AIDS. 2013 Jan 28;27(3):407-15. abstract

7 Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, P Reiss, W El- Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren, MG Law on behalf of the D:A:D Study Group. 
Journal of the International AIDS Society 2012, 15:17426 article

8 Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke SW Worm, DA Kamara, P Reiss, E Fontas, S De Wit, W El-Sadr, A D´Arminio Monforte, M Law, A Phillips, L Ryom, NF Dabis, R Weber, C Sabin, JD Lundgren, and on behalf of the D:A:D Study Group
J Infect Dis. 2012 Feb 15;205(4):535-9. abstract

9 The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, AD Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin.
J Infect Dis. 2011 Aug;204(4):521-525. abstract

10 Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study. SW Worm, DA Kamara, P Reiss, O Kirk, W El-Sadr, C Fux, E Fontas, A Phillips, AD Monforte, S De Wit, K Petoumenos, N Friis-Møller, P Mercie, J Lundgren, C Sabin.
AIDS. 2011 Jul 31;25(12):1497-504. abstract

11 Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study('). K Petoumenos, S Worm, P Reiss, S De Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, JD Lundgren, M Law; for the D:A:D study group.
HIV Med. 2011 Aug;12(7):412-21. abstract

12 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. R Weber, C Sabin, P Reiss, S De Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren.
Antivir Ther. 2010;15(8):1077-86. abstract

13 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group. C Smith, SW Worm, N Friis- Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller.
AIDS. 2010 Jun 19;24(10):1537-48. abstract

14 Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collecton on Adverse Effects of Anti-HIV Drugs Study. N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, C Sabin, JD Lundgren, M Law; for the DAD study group.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. article

15 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis- Møller N, Fontas E, Weller I, Phillips a, Lundgren J. 
J Infect Dis. 2010 Feb 1;201(3):318-30. abstract

16 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin, for the DAD study group. 
AIDS. 2010 Jan 28;24(3):427-35. abstract

17 Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study). SW Worm, CA Sabin, P Reiss, W El-Sadr, A Monforte, C Pradier, R Thiebaut, M Law, M Rickenbach, S De Wit, JD Lundgren, N Friis- Møller.
Diabetes Care. 2009 Mar;32(3):474-80. Epub 2008 Dec 3. abstract

18 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, AD Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren, N Friis-Møller.
Circulation. 2009 Feb 17;119(6):805-11. Epub 2009 Feb 2. abstract

19 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. A Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller,  AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
AIDS. 2008 Oct 18;22(16):2143-53 abstract

20 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. The SMART/INSIGHT and the D:A:D study groups. Writing committee: JD Lundgren, J Neuhaus, A Babiker, D Cooper, D Duprez, W El-Sadr, S Emery, F Gordin, J Kowalska, A Phillips, RJ Prineas, P Reiss, C Sabin, R Tracy, R Weber, B Grund and JD Neaton.
AIDS.2008, 22:F17-F24  abstract

21 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, F Dabis, S De Wit, M Law, A D´Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren. 
Lancet. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2 abstract

22 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren.
Clin Infect Dis. 2008 Apr 1;46(7):1101-10  abstract

23 Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. S de WIt, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren. 
Diabetes Care. 2008 Feb 11 abstract

24 Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A d´Arminio Monforte, W El-Sadr, R Thiebaut, S De Wit, O Kirk, E Fontas, MG Law, A Phillips, JD Lundgren on behalf of the D:A:D study group. 
N Engl J Med. 2007 April 26;356:1723-35 abstract

25 The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study. MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group.
HIV Med. 2006;7;218-230 abstract

26 Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d’Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren
Arch Intern Med. 2006;166:1632-1641 abstract

27 Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A Monforte; HBV-HIV International Intercohort Study Group. 
Antivir Ther. 2006;11(5):567-74  abstract

28 Predictors of hypertension and changes of blood pressure in HIV-infected patients. R Thiebaut, WM El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, AD Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren; Data Collection of Adverse events of anti-HIV Drugs Study Group.
Antivir Ther. 2005;10(7):811-23 abstract

29 Lipid profiles in HIV-1-infected individuals receiving combination antiretroviral therapy: are different protease inhibitors or non-nucleoside reverse transcriptase inhibitors associated with different lipid profiles?  E Fontas, F van Leth, CA Sabin, N Friis-Møller, M Rickenbach, A d’Arminio Monforte, O Kirk, M Dupon, L Morfeldt, S Mateu, K Petoumenos, W El-Sadr, S De Wit, JD Lundgren, C Pradier, P Reiss.
J Infect Dis. 2004;189(6):1056-1075 abstract

30 Cardio- and Cerebrovascular Events in HIV-Infected Persons. The Data Collection o­n Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
Writing Committee: A d'Arminio Monforte, CA Sabin, P Reiss, R Weber, O Kirk, W El-Sadr, S De Wit, S Mateu, K Petoumenos, F Dabis, C Pradier, L Morfeldt, AN Phillips, JD Lundgren, and N Friis-Moller.
AIDS 2004, 18:1811-1817 abstract

31 Modelling the three year risk of myocardial infarction among participants in the D:A:D study. M Law, N Friis-Møller, R Weber, P Reiss, R Thiebaut, O Kirk et al.
HIV Med. 2003; 4(1):1-10. abstract

32 Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. N Friis-Møller, R Weber, P Reiss, R Thiebaut, O Kirk, A d'Arminio Monforte et al.
AIDS. 2003,17:1179-1193 abstract

33 Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection o­n Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. 
Writing Committee: N Friis-Moller, CA Sabin, R Weber, A d'Arminio Monforte, WM El-Sadr, P Reiss, R Thiebaut, L Morfeldt, S De Wit, C Pradier, G Calvo, MG Law, O Kirk, AN Phillips, JD Lundgren.
N Engl J Med. 2003;349(21); 1993-2003. abstract